Personalized Melanoma Vaccine Elicits Strong Immune Response
Results of a Dana-Farber Cancer Institute-initiated Phase I clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible and improves the vaccine-specific immune response compared to previous trials of the platform.
FDA Accelerates Approval for Rare Kidney Disease
The U.S. Food and Drug Administration has granted accelerated approval for Novartis’ Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Measles: A Patient’s Perspective
When their youngest son Max became ill with measles in 1995, Rüdiger Schoenbohm and his wife, Anke, were naturally concerned. Max was only 6 months old and still too young to have been vaccinated.
New Data Show One in 31 Kids Has Autism
Autism prevalence in the U.S. has increased from one in 36 children to one in 31, according to the Centers for Disease Control and Prevention’s (CDC) latest Autism and Developmental Disabilities Monitoring (ADDM) Network survey.
COVID-19 May Increase IVIG-Resistance in Kids Prior to Developing Kawasaki Disease
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
Measles: A Physician’s Perspective
George Rust, MD, MPH, joined the faculty of the Florida State University (FSU) College of Medicine in 2016 and serves as medical director for six local county public health department. He is the author of a 2025 measles fact sheet to help address this important public health concern.
Activating B Cells Key to TIL Cancer Therapy Effectiveness
Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.
FDA Approves Gammagard Liquid ERC to Treat PI, Plans to Discontinue Gammagard SD in December 2027
The U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for individuals 2 years of age and older with primary immunodeficiency (PI).
Update on Measles
Once eradicated in the U.S., measles is now on the rise due to a growing mistrust of public health guidance, but it is highly preventable with vaccination.
Vaccine Advisers Recommend New RSV Vaccine for Infants
A group of outside advisers to the Centers for Disease Control and Prevention (CDC) voted 5-2 to recommend the use of Merck’s new antibody vaccine, Enflonsia (clesrovimab), that can protect babies from respiratory syncytial virus (RSV).
